Status:
RECRUITING
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18-70 years
Brief Summary
Multiple myeloma (MM) is a malignant proliferative plasma cell disease, which accounts for approximately 10% and ranks secondly of hematological malignancies in many countries. It is more common in th...
Detailed Description
Multiple myeloma (MM) is a malignant proliferative plasma cell disease, which accounts for approximately 10% and ranks secondly of hematological malignancies in many countries. It is more common in th...
Eligibility Criteria
Inclusion
- Age 18-70 years old
- Patients diagnosed multiple myeloma by bone marrow cytology
- Trends to be hospitalized and treated by RVd induction therapy
- Be able to complete at least 3-4 cycles treatment
Exclusion
- Simultaneously diagnosed myocardial amyloidosis or other systemic amyloidosis
- Severe cardiovascular diseases such as myocardial infarction, heart failure, or previous surgery such as bypass grafting or valve replacement
- Severe arrhythmia such as atrial fibrillation
- Poor echocardiographic image quality
Key Trial Info
Start Date :
November 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06039735
Start Date
November 16 2023
End Date
December 1 2028
Last Update
November 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu hospital of Shandong university
Jinan, Shandong, China